chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Eructation, Headache, Pain in extremity
Clinical narrative: sore arm, extremely painful arm; chest felt tight; belching; light headed; finding hard to stand up; hard to breath; feeling weak; headache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm, extremely painful arm), CHEST DISCOMFORT (chest felt tight), ERUCTATION (belching), DIZZINESS (light headed) and DYSSTASIA (finding hard to stand up) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history reported.  Concomitant products included BENZTROPINE [BENZATROPINE], ACETYLSALICYLIC ACID (BABY ASPIRIN) and VITAMIN D NOS for an unknown indication.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, the patient experienced PAIN IN EXTREMITY (sore arm, extremely painful arm), ERUCTATION (belching), DIZZINESS (light headed), DYSSTASIA (finding hard to stand up) and HEADACHE (headache). 18-Feb-2021, the patient experienced CHEST DISCOMFORT (chest felt tight), DYSPNOEA (hard to breath) and ASTHENIA (feeling weak). On 18-Feb-2021, HEADACHE (headache) had resolved. At the time of the report, PAIN IN EXTREMITY (sore arm, extremely painful arm), CHEST DISCOMFORT (chest felt tight), ERUCTATION (belching), DIZZINESS (light headed), DYSSTASIA (finding hard to stand up), DYSPNOEA (hard to breath) and ASTHENIA (feeling weak) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient was taking concomitant medication for her mental condition and blood thinner.  Treatment medication was not reported.  Patient got their first dose of the Moderna vaccine on 16 Feb 2021, on their right arm and had a sore arm at first. Woke up around 5am with an extremely painful arm, their chest felt tight, they were belching and had a headache. the went back to bed and then woke up at 7:30am, feeling light headed, hard to breath, and still with a headache that has now subsided. Now patient is still belching and feeling weak, finding hard to stand up. Patient did not have lot number at hand.
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site mass, Injection site pruritus
Clinical narrative: begin to itch like crazy; lump on injection site; red lump at injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PRURITUS (begin to itch like crazy), INJECTION SITE MASS (lump on injection site) and INJECTION SITE ERYTHEMA (red lump at injection site) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Acid reflux (oesophageal), Anxiety, Thyroid disorder and Hypertension.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE PRURITUS (begin to itch like crazy), INJECTION SITE MASS (lump on injection site) and INJECTION SITE ERYTHEMA (red lump at injection site). The patient was treated with HYDROCORTISONE at an unspecified dose and frequency. At the time of the report, INJECTION SITE PRURITUS (begin to itch like crazy), INJECTION SITE MASS (lump on injection site) and INJECTION SITE ERYTHEMA (red lump at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication includes blood pressure meds, thyroid med, anxiety med, acid reflux med. Treatment medication include allergy pills.; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.  Injection site itching, injection site erythema and injection site mass are consistent with the product safety profile.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site rash, Vaccination site swelling
Clinical narrative: rash at injection site that creeps down arm, size of a dollar bill; swelling in arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash at injection site that creeps down arm, size of a dollar bill) and VACCINATION SITE SWELLING (swelling in arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE RASH (rash at injection site that creeps down arm, size of a dollar bill) and VACCINATION SITE SWELLING (swelling in arm). The patient was treated with Corisone10 at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (rash at injection site that creeps down arm, size of a dollar bill) outcome was unknown and VACCINATION SITE SWELLING (swelling in arm) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the events, a causal relationship cannot be excluded.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Off label use
Clinical narrative: Doctor cancelled her appointment for second dose; tested positive; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (tested positive) and OFF LABEL USE (Doctor cancelled her appointment for second dose) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025120A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced COVID-19 (tested positive). On an unknown date, the patient experienced OFF LABEL USE (Doctor cancelled her appointment for second dose). The patient was treated with MONOCLONAL ANTIBODY 17-1A ongoing since an unknown date for Adverse event, at a dose of UNK dosage form. At the time of the report, COVID-19 (tested positive) outcome was unknown and OFF LABEL USE (Doctor cancelled her appointment for second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient went to emergency room  on 02-Feb-2021 and received the monoclonal antibody infusion.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site mass, Vaccination site rash
Clinical narrative: Rash in the site of injection; Lump in the injection site; A spontaneous report was received from a consumer concerning a 69-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced vaccination site  rash and vaccination site mass.   The patient's medical history was not provided. No relevant concomitant medications were reported.  On 8 Feb 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: 012M20A) via unknown route for prophylaxis of COVID-19 infection.  On 17 Feb 2021, the patient experienced the event(s) vaccination site rash, and vaccination site mass.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), rash in the site of injection, lump in the site of injection was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Headache, Hypertension, Injection site pain
Clinical narrative: headache that felt like migraine; high blood pressure; Soreness at the injection site; This spontaneous case was reported by an other (subsequently medically confirmed) and describes the occurrence of INJECTION SITE PAIN (Soreness at the injection site), HEADACHE (headache that felt like migraine) and HYPERTENSION (high blood pressure) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     The patient's past medical history included Vertigo and Stroke.    On 18-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced INJECTION SITE PAIN (Soreness at the injection site). On 24-Jan-2021, the patient experienced HEADACHE (headache that felt like migraine) and HYPERTENSION (high blood pressure). The patient was treated with IBUPROFEN (EXCEDRIN IB) at an unspecified dose and frequency and NAPROXEN (NAPROSYN E) at an unspecified dose and frequency. At the time of the report, INJECTION SITE PAIN (Soreness at the injection site), HEADACHE (headache that felt like migraine) and HYPERTENSION (high blood pressure) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded. Headache and injection site pain are consistent with the product safety profile
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Swelling face, Swelling of eyelid, Vaccination complication, Vaccination site pain
Clinical narrative: Vaccination adverse reaction; rash in th face; Sore arm; swelling face; eyelids red and swollen; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore arm), SWELLING FACE (swelling face), SWELLING OF EYELID (eyelids red and swollen), VACCINATION COMPLICATION (Vaccination adverse reaction) and RASH (rash in th face) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, the patient experienced VACCINATION SITE PAIN (Sore arm), SWELLING FACE (swelling face), SWELLING OF EYELID (eyelids red and swollen) and RASH (rash in th face). On an unknown date, the patient experienced VACCINATION COMPLICATION (Vaccination adverse reaction). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (Sore arm), SWELLING OF EYELID (eyelids red and swollen) and RASH (rash in th face) had not resolved and SWELLING FACE (swelling face) and VACCINATION COMPLICATION (Vaccination adverse reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.     Most recent FOLLOW-UP information incorporated above includes: On 25-May-2021: significant follow up On 25-May-2021: Non Significant follow up
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Lacrimation increased, Nasal congestion, Rhinorrhoea
Clinical narrative: Nasal Congestion; Runny nose; Watery eyes; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (Nasal Congestion), RHINORRHOEA (Runny nose) and LACRIMATION INCREASED (Watery eyes) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 030L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No prior medical history was reported.).   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Jan-2021, the patient experienced NASAL CONGESTION (Nasal Congestion), RHINORRHOEA (Runny nose) and LACRIMATION INCREASED (Watery eyes). At the time of the report, NASAL CONGESTION (Nasal Congestion), RHINORRHOEA (Runny nose) and LACRIMATION INCREASED (Watery eyes) outcome was unknown.            The patient's medical history was not provided but the patient claims that he has no history of allergies.  Concomitant product use was not provided. Treatment details included the use of fexofenadine.; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy
Clinical narrative: Vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) in a 42-year-old female patient (gravida 3, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011M2(orZ)0A and 011M2(orZ)0A) for COVID-19 vaccination.     Concurrent medical conditions included Pregnant since 09-Feb-2021 and Drug allergy (Levofloxacin). Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]), LORATADINE, SERTRALINE, FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]), BUPROPION HYDROCHLORIDE (WELLBUTRIN XL) and VITAMIN D [VITAMIN D NOS] for an unknown indication.   On 07-Jan-2021 at 3:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021 at 2:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 09-Nov-2020 and the estimated date of delivery was 27-Sep-2021. On 07-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  eighth week of the pregnancy.  On 04-Feb-2021, EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) had resolved.; Sender's Comments: This case concerns a 42-Year-old female with missing obstetric history who received mRNA-1273 while pregnant (vaccine exposure during pregnancy). The patient's  last menstrual period, estimated date of conception and delivery is lacking. Vaccine exposure during pregnancy is assessed as not applicable.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Injection site pruritus, Injection site rash, Pyrexia, Vaccination site erythema
Clinical narrative: injection site pruitus; injection site rash; A big red spot around the injection site; Skin is so warm that when they measured it was 100 degrees; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INJECTION SITE PRURITUS (injection site pruitus), INJECTION SITE RASH (injection site rash), VACCINATION SITE ERYTHEMA (A big red spot around the injection site) and PYREXIA (Skin is so warm that when they measured it was 100 degrees) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     Concurrent medical conditions included Breast cancer.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, the patient experienced INJECTION SITE PRURITUS (injection site pruitus), INJECTION SITE RASH (injection site rash), VACCINATION SITE ERYTHEMA (A big red spot around the injection site) and PYREXIA (Skin is so warm that when they measured it was 100 degrees). At the time of the report, INJECTION SITE PRURITUS (injection site pruitus), INJECTION SITE RASH (injection site rash), VACCINATION SITE ERYTHEMA (A big red spot around the injection site) and PYREXIA (Skin is so warm that when they measured it was 100 degrees) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Feb-2021, Body temperature: 100 f High.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 26-Apr-2021: Non significant follow up received on 26-APR-2021, no new information; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded. Fever, injection site rash, injection site erythema and injection site pruritus are consistent with the product safety profile
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vomiting
Clinical narrative: Vomiting like nonstop; Very nauseated; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (Vomiting like nonstop) and NAUSEA (Very nauseated) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history provided).    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jan-2021, the patient experienced VOMITING (Vomiting like nonstop) and NAUSEA (Very nauseated). At the time of the report, VOMITING (Vomiting like nonstop) and NAUSEA (Very nauseated) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded. The reported events are consistent with the product safety profile
Age: 86.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: massive bloody nose that lasted for two hours; This spontaneous case was reported by a physician and describes the occurrence of EPISTAXIS (massive bloody nose that lasted for two hours) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Feb-2021, the patient experienced EPISTAXIS (massive bloody nose that lasted for two hours). On 17-Feb-2021, EPISTAXIS (massive bloody nose that lasted for two hours) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   blood thinners were included as concomitant medications; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Diarrhoea, Pyrexia
Clinical narrative: Severe diarrhea; Stomach crumps; Fever; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Severe diarrhea), ABDOMINAL PAIN UPPER (Stomach crumps) and PYREXIA (Fever) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011M-20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Feb-2021, the patient experienced DIARRHOEA (Severe diarrhea), ABDOMINAL PAIN UPPER (Stomach crumps) and PYREXIA (Fever). At the time of the report, DIARRHOEA (Severe diarrhea) and ABDOMINAL PAIN UPPER (Stomach crumps) had not resolved and PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. Treatment medication include Gas tablet.; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the event, a causal relationship cannot be excluded. Fever is consistent with the product safety profile
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Glucose tolerance test, Maternal exposure during pregnancy, Oophorectomy, Pregnancy test, Ultrasound uterus normal
Clinical narrative: Vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by an other and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) in a 31-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026120A and 041L20A) for COVID-19 vaccination.     Concomitant products included CETIRIZINE HYDROCHLORIDE (CETRIZINE) for Allergy, MACROGOL 3350 (MIRALAX) for Constipation, MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for Pregnancy, DOCUSATE SODIUM (COLACE), CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) and ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE (PEPCID [ALUMINIUM HYDROXIDE GEL, DRIED;MAGNESIUM CARBONATE]) for an unknown indication.   On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 02-Jul-2020 and the estimated date of delivery was 08-Apr-2021. On 04-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-sixth week of the pregnancy.  On 04-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Aug-2020, Pregnancy test: positive (Positive) positive. In December 2020, Oophorectomy: abnormal (abnormal) minor surgery- ovary removed -prior to vaccination. In January 2021, Glucose tolerance test: unknown (Inconclusive) unknown. On an unknown date, Ultrasound uterus normal: normal (normal) 18 week done, choroid plexus cyst , resolved..     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Estimated date of conception reported was 20-Jul-2020.   Most recent FOLLOW-UP information incorporated above includes: On 28-Apr-2021: Follow up received on 28 April 2021. Informations on patient demographics and concomitant medications were added.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site mass, Vaccination site pruritus
Clinical narrative: Injection site bumpy; Injection site Itching like crazy; Injection site super red; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE MASS (Injection site bumpy), VACCINATION SITE PRURITUS (Injection site Itching like crazy) and VACCINATION SITE ERYTHEMA (Injection site super red) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 062G20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and Thrombocytosis.   On 12-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, the patient experienced VACCINATION SITE MASS (Injection site bumpy), VACCINATION SITE PRURITUS (Injection site Itching like crazy) and VACCINATION SITE ERYTHEMA (Injection site super red). The patient was treated with CIPROFLOXACIN (BACTIN [CIPROFLOXACIN]) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE MASS (Injection site bumpy), VACCINATION SITE PRURITUS (Injection site Itching like crazy) and VACCINATION SITE ERYTHEMA (Injection site super red) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medicine includes high blood pressure medicine and a pill (because they have too many platelets). Action taken with mRNA-1273 in response to the event was not applicable.; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded. The reported events are consistent with the product safety profile
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Insomnia, Maternal exposure during pregnancy, Pain in extremity, Ultrasound foetal
Clinical narrative: My arm was sore; Hard time sleeping; Pregnant and received the first dose of the moderna; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant and received the first dose of the moderna) and INSOMNIA (Hard time sleeping) in a 28-year-old female patient (gravida 2, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     Previously administered products included for an unreported indication: ALCOHOL (2 drinks per week.) until 01-Dec-2020. Concurrent medical conditions included Fruit allergy (Grapes). Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) from 07-Dec-2020 to an unknown date for Prenatal care, IRON from 07-Dec-2020 to an unknown date for an unknown indication.    On 11-Feb-2021 at 11:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 10-Nov-2020 and the estimated date of delivery was 17-Aug-2021. On 11-Feb-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant and received the first dose of the moderna). On 12-Feb-2021, the patient experienced INSOMNIA (Hard time sleeping). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirteenth week of the pregnancy.  On 11-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant and received the first dose of the moderna) had resolved. On 13-Feb-2021, INSOMNIA (Hard time sleeping) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Jan-2021, Ultrasound foetal: normal (normal) 9 week ultrasound - No abnormal findings.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Date of positive pregnancy test was 07 Dec 2020. Estimated date of conception was 13 to 15 Nov 2020. No treatment information was reported.   This case was linked to MOD-2021-272233 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2021: Reporter address, patient demographics, second dose details and event hard time sleeping were updated; Sender's Comments: This is a case of product exposure during pregnancy with associated AEs for this 28-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy. Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Listless, Pain in extremity
Clinical narrative: listlessness; very sore arm; This spontaneous case was reported by a consumer and describes the occurrence of LISTLESS (listlessness) and PAIN IN EXTREMITY (very sore arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included LOSARTAN, ATORVASTATIN CALCIUM (LIPITOR) and WARFARIN for an unknown indication.   On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 2 dosage form. On 17-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Feb-2021, the patient experienced LISTLESS (listlessness) and PAIN IN EXTREMITY (very sore arm). At the time of the report, LISTLESS (listlessness) and PAIN IN EXTREMITY (very sore arm) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information not provided.   This case was linked to MOD-2021-015944 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Little bit of a sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Little bit of a sore arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Little bit of a sore arm). At the time of the report, PAIN IN EXTREMITY (Little bit of a sore arm) had resolved.            No concomitant medication was reported.  Treatment medication was not provided by the reporter.  Action taken with mRNA-1273 in response to the event was not applicable.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Pain, Paraesthesia
Clinical narrative: Pain; tingling; numbness; A spontaneous report (United States) was received from a consumer concerning a 78-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events pain, tingling, numbness.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 6 Feb 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: 039K20A) intramuscularly for prophylaxis of COVID-19 infection.  On 3 Feb 2021, the patient experienced the event(s) pain, tingling, numbness.  No treatment information was provided. Action taken with mRNA-1273 in response to the events was not reported.   On 3 Feb 2021 the outcome of event(s), pain, tingling, numbness was resolved.; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.
Sex: M
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History was provided by the reporter.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.  On 17-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form.   On 17-Feb-2021, the patient experienced HEADACHE (Headache). The patient was treated with PRIMIDONE at a dose of 1 dosage form; METOPROLOL TARTRATE at a dose of 1 dosage form; ATORVASTATIN CALCIUM (LIPITOR) at a dose of 1 dosage form; WARFARIN at a dose of 1 dosage form; TAMSULOSIN at a dose of 1 dosage form and AMLODIPINE BESYLATE at a dose of 1 dosage form. On 17-Feb-2021, HEADACHE (Headache) had resolved.      Concomitant product use was not provided by the reporter.    This case was linked to MOD-2021-015941 (Patient Link).
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Hypertension
Clinical narrative: high blood pressure; This spontaneous case was reported by a consumer and describes the occurrence of HYPERTENSION (high blood pressure) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced HYPERTENSION (high blood pressure). At the time of the report, HYPERTENSION (high blood pressure) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's medical history and concomitant medications were reported. Treatment information was not provided; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Depressed mood, Pain, Rash macular
Clinical narrative: Swollen red spot; broke it.; painful.; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (Swollen red spot), PAIN (painful.) and DEPRESSED MOOD (broke it.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH MACULAR (Swollen red spot), PAIN (painful.) and DEPRESSED MOOD (broke it.). At the time of the report, RASH MACULAR (Swollen red spot), PAIN (painful.) and DEPRESSED MOOD (broke it.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy
Clinical narrative: Vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a patient and describes the occurrence of EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) in a 34-year-old female patient (gravida 4, para 2) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013L20A and 030M20A) for COVID-19 vaccination.     The patient's past medical history included Alcohol addiction (1-2 glasses of wine per week) on 03-Feb-2021. Concurrent medical conditions included Pregnancy (she received first dose of vaccine prior to aware of pregnancy. she is in the process of prenatal care) on 03-Feb-2021. Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for Vitamin supplementation and Pregnancy.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. The patient's last menstrual period was on 01-Jan-2021 and the estimated date of delivery was 08-Oct-2021. On 20-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  second week of the pregnancy. The delivery occurred on an unknown date. For neonate 1, Number of previous pregnancies-4 1st pregnancy end date -27-07-2016 2nd pregnancy undergone  miscarriage in June 2018 and 3rd pregnancy went miscarriage  in mar 2019. 4th pregnancy due date 08-10-2021. At the time of the report, EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) had resolved.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site induration, Vaccination site pruritus, Vaccination site warmth
Clinical narrative: Hot; Hard; Itchy; 2 1/2 inch diameter spot at injection site that is red; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Hot), VACCINATION SITE INDURATION (Hard), VACCINATION SITE PRURITUS (Itchy) and VACCINATION SITE ERYTHEMA (2 1/2 inch diameter spot at injection site that is red) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (Hot), VACCINATION SITE INDURATION (Hard), VACCINATION SITE PRURITUS (Itchy) and VACCINATION SITE ERYTHEMA (2 1/2 inch diameter spot at injection site that is red). At the time of the report, VACCINATION SITE WARMTH (Hot), VACCINATION SITE INDURATION (Hard), VACCINATION SITE PRURITUS (Itchy) and VACCINATION SITE ERYTHEMA (2 1/2 inch diameter spot at injection site that is red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 95.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Headache, Pain in extremity, Peripheral swelling, Skin swelling
Clinical narrative: the back of her arm where she had the vaccine all the way down was swollen; puffy; slight headache; sore arm; it was really bad; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm), FEELING ABNORMAL (it was really bad), PERIPHERAL SWELLING (the back of her arm where she had the vaccine all the way down was swollen), SKIN SWELLING (puffy) and HEADACHE (slight headache) in a 95-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011HZ0A) for COVID-19 vaccination.     No medical history was provided by the reporter.  The patient's past medical history included No adverse event. Concomitant products included CLONAZEPAM for an unknown indication.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Feb-2021, the patient experienced PAIN IN EXTREMITY (sore arm), FEELING ABNORMAL (it was really bad) and HEADACHE (slight headache). On 18-Feb-2021, the patient experienced PERIPHERAL SWELLING (the back of her arm where she had the vaccine all the way down was swollen) and SKIN SWELLING (puffy). At the time of the report, PAIN IN EXTREMITY (sore arm), FEELING ABNORMAL (it was really bad), PERIPHERAL SWELLING (the back of her arm where she had the vaccine all the way down was swollen), SKIN SWELLING (puffy) and HEADACHE (slight headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site mass, Injection site pain, Injection site rash, Type IV hypersensitivity reaction
Clinical narrative: COVID Arm; injection site lump; injection site pain/ injection site achy; injection site rash; This spontaneous case was reported by a consumer and describes the occurrence of TYPE IV HYPERSENSITIVITY REACTION (COVID Arm), INJECTION SITE MASS (injection site lump), INJECTION SITE PAIN (injection site pain/ injection site achy) and INJECTION SITE RASH (injection site rash) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     Concurrent medical conditions included Sulfonamide allergy.    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, the patient experienced TYPE IV HYPERSENSITIVITY REACTION (COVID Arm), INJECTION SITE MASS (injection site lump), INJECTION SITE PAIN (injection site pain/ injection site achy) and INJECTION SITE RASH (injection site rash). At the time of the report, TYPE IV HYPERSENSITIVITY REACTION (COVID Arm), INJECTION SITE MASS (injection site lump), INJECTION SITE PAIN (injection site pain/ injection site achy) and INJECTION SITE RASH (injection site rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Dizziness, Headache, Pyrexia
Clinical narrative: Dizziness; Loss of taste and smell; Loss of taste and smell; Headache; Fever; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), ANOSMIA (Loss of taste and smell), HEADACHE (Headache) and PYREXIA (Fever) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Feb-2021, the patient experienced DIZZINESS (Dizziness), ANOSMIA (Loss of taste and smell), HEADACHE (Headache) and PYREXIA (Fever). At the time of the report, DIZZINESS (Dizziness), ANOSMIA (Loss of taste and smell), HEADACHE (Headache) and PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Fatigue, Feeling hot, Headache
Clinical narrative: My head is hot; Weak/tired; Mild headache; Weak/tired; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (My head is hot), ASTHENIA (Weak/tired), HEADACHE (Mild headache) and FATIGUE (Weak/tired) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported).    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FEELING HOT (My head is hot), ASTHENIA (Weak/tired), HEADACHE (Mild headache) and FATIGUE (Weak/tired). At the time of the report, FEELING HOT (My head is hot), ASTHENIA (Weak/tired), HEADACHE (Mild headache) and FATIGUE (Weak/tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Contusion, Rash pruritic
Clinical narrative: Itching rash; Bruise mark at injection site; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of CONTUSION (Bruise mark at injection site) and RASH PRURITIC (Itching rash) in an 85-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no reported medical history).    On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, the patient experienced CONTUSION (Bruise mark at injection site). On 03-Feb-2021, the patient experienced RASH PRURITIC (Itching rash). At the time of the report, CONTUSION (Bruise mark at injection site) and RASH PRURITIC (Itching rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Severe itchiness that started in legs and spread to whole body; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Severe itchiness that started in legs and spread to whole body) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included LEVOTHYROXINE, MONTELUKAST SODIUM (SINGULAIR), AMOXICILLIN TRIHYDRATE, CLARITHROMYCIN, ESOMEPRAZOLE MAGNESIUM (NEXIUM 1-2-3), MULTIVITAMINS & MINERALS PLUS LUTEIN and ESTROGENS CONJUGATED (ESTROL) for an unknown indication.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, the patient experienced PRURITUS (Severe itchiness that started in legs and spread to whole body). At the time of the report, PRURITUS (Severe itchiness that started in legs and spread to whole body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient did not take anything to treat but did drink water till cooling down.
Sex: U
Vaccine: COVID19
Symptoms: Nausea, Pyrexia
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever) and NAUSEA (nausea) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. #74802) for COVID-19 vaccination. The patient's past medical history included Shingles and Nerve damage. On 17-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 2 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, the patient experienced PYREXIA (fever) and NAUSEA (nausea). At the time of the report, PYREXIA (fever) and NAUSEA (nausea) outcome was unknown.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Arm is aching around the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Arm is aching around the injection site) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 25-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Arm is aching around the injection site). At the time of the report, VACCINATION SITE PAIN (Arm is aching around the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Rash macular
Clinical narrative: Patient had a blotchy rash on his whole torso; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (Patient had a blotchy rash on his whole torso) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced RASH MACULAR (Patient had a blotchy rash on his whole torso). At the time of the report, RASH MACULAR (Patient had a blotchy rash on his whole torso) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.